CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2006; 27(03): 12-19
DOI: 10.1055/s-0041-1733171
Review

Anticancer Drug Discovery: Role of Pharmacogenomics

Abhijit Ray
Department of New Drug Discovery Research, Ranbaxy Laboratories Ltd., Udyog Vihar Industrial Area, Gurgaon, Haryana 122001, India
› Author Affiliations


Publication History

Article published online:
23 March 2022

© 2006. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
  • References

  • 1 Innocenti F, Ratain MJ. Update on pharmacogentics in cancer chemotherapy. Eur J Cancer 2002;38:639-44.
  • 2 Evans WE. Pharmacogenomics: Marshalling the human genome to individualise drug therapy. Gut 2003;52 (Suppl 2): ii 10-ii 18.
  • 3 Innocenti F, Iyer L, Ratain MJ. Pharmacogenetics : tool for individualizing antineoplastic therapy. Cliin Pharmacokinet 2000;39:315-325.
  • 4 Evans WE, Hon YY, Bomgaars L et al. Preponderance of TPMT deficiency and heterozygosity amongst patients intolerant to mercaptopurine/azathioprine. J Clin Oncol 2001;19:2293-2301.